Current Studies
Acute HIV Studies at UNC
CID 0804: Longitudinal (CTRC 2134) – Acute HIV Longitudinal Study
| POP: | Individuals diagnosed with Acute HIV Infection | |
| CALL: | Francesca Prince, 919-966-8794 or 919-428-7612 or Caroline Baker, 919-966-2623 |
PHI 05: QD Therapy with Dolutegravir/Epzicom for Acute HIV Infection
| Q: | Treatment of Acute HIV Infection with one tablet once a day | |
| POP: | Acute HIV infection | |
| MED: | Fixed-dose combination of dolutegravir and epzicom Substudy: Leukapheresis |
|
| DUR: | 5 years (medication provided for 2 years) | |
| CALL: | Kristen Hancock, RN, 919-843-6848 |
A5354: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
| Q: |
Timing of antiretroviral therapy (ART) during different stages of acute HIV-1 infection (AHI) will be predictive of the magnitude and characteristics of HIV-1 reservoirs, and the quantity and quality of HIV-1-specific immune responses at week 48. |
|
| POP: |
Men and women 18 years and older with AHI. Group 1: Fiebig I/II (non-reactive HIV-1 antibody) Group 2: Fiebig III/IV (reactive HIV-1 antibody and negative or indeterminate results on the Western blot or Geenius HIV-1/HIV-2) Group 3: Fiebig V (reactive HIV-1 antibody and positive Western blot or Geenius HIV-1/HIV-2 without p31 band) |
|
| MED: |
The antiretroviral (ARV) regimen provided through the study is the single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF). Other non-study-provided ARV regimens will be allowed for participants who are pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF, or for participants whose local health care/primary care provider prefers starting a different initial ARV regimen. |
|
| DUR: |
Up to 72 weeks. |
|
| CALL: |
Kristen Hancock, RN, BSN, 919-843-6848 or Susan Pedersen, RN, 919-966-6713 |